Holen Sie sich die Stockscreener-App
551.25
1.24%
6.74
Handel nachbörslich:
553.68
2.43
+0.44%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MDGL?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$544.51
Offen:
$555
24-Stunden-Volumen:
276.53K
Relative Volume:
0.86
Marktkapitalisierung:
$12.71B
Einnahmen:
$1.13B
Nettoeinkommen (Verlust:
$-309.44M
KGV:
-43.07
EPS:
-12.8001
Netto-Cashflow:
$-275.41M
1W Leistung:
+2.90%
1M Leistung:
+7.53%
6M Leistung:
+10.16%
1J Leistung:
+84.74%
1-Tages-Spanne:
$548.68
$566.18
1-Wochen-Bereich:
$526.61
$566.18
52-Wochen-Spanne:
$286.44
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Firmenname
Madrigal Pharmaceuticals Inc
Sektor
Branche
Telefon
404-380-9263
Adresse
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
551.25 | 12.55B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-02-28 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Bestätigt | H.C. Wainwright | Buy |
| 2024-06-28 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2024-04-22 | Eingeleitet | BofA Securities | Underperform |
| 2024-03-15 | Hochstufung | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-02-26 | Herabstufung | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Bestätigt | Oppenheimer | Outperform |
| 2022-12-19 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-19 | Bestätigt | Piper Sandler | Overweight |
| 2022-12-19 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-08-06 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Fortgesetzt | Goldman | Buy |
| 2020-11-24 | Fortgesetzt | Evercore ISI | Outperform |
| 2020-11-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-05 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-05-05 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-01-30 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-01-09 | Hochstufung | UBS | Neutral → Buy |
| 2019-11-07 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-06-10 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-01-23 | Eingeleitet | UBS | Neutral |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-12-12 | Eingeleitet | B. Riley FBR | Neutral |
| 2018-11-19 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Eingeleitet | Citigroup | Buy |
| 2018-08-06 | Herabstufung | Goldman | Buy → Neutral |
| 2018-06-28 | Eingeleitet | Raymond James | Mkt Perform |
Alle ansehen
Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten
Madrigal Pharmaceuticals Inc (MDGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MDGL Initiated Coverage by Wells Fargo -- Rating Set to Overweig - GuruFocus
Madrigal Pharmaceuticals, Inc. Revenue Breakdown – XETR:YDO1 - TradingView
Madrigal Pharmaceuticals Inc (MDGL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Raises Target Price to $553 - Moomoo
Madrigal Pharmaceuticals CEO Sibold sells $1.37 million in shares By Investing.com - Investing.com Australia
UBS Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $669 - Moomoo
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal New Hires Receive Options With $550.25 Exercise Price - Stock Titan
Form 4 Madrigal Pharmaceuticals Inc For: 21 July By Investing.com - Investing.com South Africa
Form 144 Madrigal Pharmaceuticals For: 21 July By Investing.com - Investing.com Nigeria
Madrigal Pharmaceuticals CEO Sibold sells $1.37 million in shares - Investing.com
Madrigal Pharmaceuticals (MDGL) insider files Form 144 for 2,500-share sale - Stock Titan
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Exploring a 22.65% Potential Upside - DirectorsTalk Interviews
Trading the Move, Not the Narrative: (MDGL) Edition - Stock Traders Daily
Citizens JMP Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $739 - Moomoo
Citizens raises Madrigal Pharmaceuticals price target on lower tax assumptions - Investing.com Nigeria
Madrigal management to discuss Q2 results at 8 a.m. Eastern July 30 - Stock Titan
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026 - The Manila Times
Is Madrigal Pharmaceuticals (MDGL) Fully Valued Ahead Of Its July 30 Earnings? - Sahm
Guojin Securities: The MASH sector is seeing intensive, multi‑dimensional catalysts come to fruition, and Madrigal is expected to maintain double-digit growth over the long term. - Moomoo
Lobbying Update: $120,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed | MDGL Stock News - Quiver Quantitative
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD) - The Globe and Mail
BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Maintains Target Price $542 - Moomoo
MDGL Stock In Focus — Retail Traders Buzz Over M&A Speculation And Pipeline Moves - Yahoo Finance
Madrigal Pharmaceuticals' Three New Patents Support Patent Extension Into 2045, Truist Says - Moomoo
Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio - BioBuzz
Madrigal receives three new U.S. patents for resmetirom drug - Investing.com
Madrigal receives three new U.S. patents for resmetirom drug By Investing.com - Investing.com South Africa
Madrigal Pharmaceuticals (MDGL) Secures New Patents to Enhance I - GuruFocus
New Rezdiffra patents extend Madrigal’s MASH IP into cirrhosis care - Stock Titan
Madrigal Grants Equity Awards to Seven New Employees - MyChesCo
Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $964 - Moomoo
Madrigal Pharmaceuticals, Inc. (MDGL) Investor Outlook: Unpacking a 26.46% Potential Upside - DirectorsTalk Interviews
Madrigal Pharmaceuticals Slides 4.2% as Clear Negative Catalyst Remains Hard to Pin Down - Quiver Quantitative
3 Under-the-Radar Stocks to Buy and Hold - Yahoo Finance
BofA lowers its Price Target on Madrigal Pharmaceuticals, Inc. (MDGL) - Insider Monkey
5 Best Under-the-Radar Stocks to Invest In - Insider Monkey
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: Navigating a Promising 28.52% Upside Potential - DirectorsTalk Interviews
Madrigal gives seven new employees stock awards to join the company - Stock Titan
MDGLMadrigal Pharmaceuticals Inc Latest SEC Filings - Finviz
Ribocure and Madrigal nominate siRNA drug candidate for MASH - BioWorld News
Enterprise value to EBITDA forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Ribo and Madrigal Reach First Major Milestone in Advancing Novel siRNA Therapies for MASH - Lelezard
Madrigal and Ribo start IND-enabling studies after MASH milestone - Stock Titan
Enterprise value to revenue forward of Madrigal Pharmaceuticals, Inc. – NASDAQ:MDGL - TradingView
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating - Investing.com
Piper Sandler reiterates Madrigal Pharmaceuticals stock rating By Investing.com - Investing.com Canada
Piper Sandler Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $900 - Moomoo
Finanzdaten der Madrigal Pharmaceuticals Inc-Aktie (MDGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):